Nestin: A biomarker of aggressive uterine cancers

Erica R. Hope, Paulette Mhawech-Fauceglia, Tanja Pejovic, Christopher M. Zahn, Guisong Wang, Thomas P. Conrads, G. Larry Maxwell, Chad A. Hamilton, Kathleen M. Darcy, Viqar Syed

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective Evidence of potential prognostic and predictive value for nestin was investigated in well-annotated uterine cancers (UCs). Methods Nestin expression and previously-published biomarkers were evaluated by immunohistochemistry (IHC) in UC tissue microarrays. Biomarkers were categorized as low vs. high, and nestin was cut at 10% positive staining. Relationship between nestin and clinicopathologic factors, biomarkers and outcome were evaluated using exact/log-rank testing or logistic/Cox modeling. Results There were 323 eligible cases, 34% had advanced stage disease, 37% had type II disease, and 5% were carcinosarcomas. High nestin, observed in 19% of cases, was more common in advanced vs. early stage disease, type II cancers or uterine carcinosarcoma vs. type I cancers, grade 3 disease, positive lymphovascular space invasion (LVSI) and tumors > 6 cm (p <0.05). Nestin was inversely correlated with ER, PR and TFF3, and correlated with p53 and IMP3. Women with high vs. low nestin had worse progression-free survival (PFS) and cancer-specific survival overall, and worse PFS in the subset who received no adjuvant therapy or radiation, or had early stage, type I disease or tumors with both low and high ER, PR, TFF3, PTEN, p53 or IMP3. The relationship between nestin and PFS was independent of stage, LVSI and risk categorization but not type of UC. Conclusions High nestin was more common in UCs with aggressive features and poor outcome. Nestin may represent a predictive biomarker for treatment selection for patients previously considered to be lower risk and a candidate for no or radiation-based adjuvant therapy, and compliment ER/PR testing.

Original languageEnglish (US)
Pages (from-to)503-511
Number of pages9
JournalGynecologic Oncology
Volume140
Issue number3
DOIs
StatePublished - Mar 1 2016

Fingerprint

Nestin
Uterine Neoplasms
Biomarkers
Disease-Free Survival
Carcinosarcoma
Neoplasms
Patient Selection
Radiotherapy
Immunohistochemistry
Radiation
Staining and Labeling

Keywords

  • Biomarkers
  • Immunohistochemistry
  • Nestin
  • Predictive
  • Prognostic
  • TMA
  • Uterine cancer

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Hope, E. R., Mhawech-Fauceglia, P., Pejovic, T., Zahn, C. M., Wang, G., Conrads, T. P., ... Syed, V. (2016). Nestin: A biomarker of aggressive uterine cancers. Gynecologic Oncology, 140(3), 503-511. https://doi.org/10.1016/j.ygyno.2015.12.015

Nestin : A biomarker of aggressive uterine cancers. / Hope, Erica R.; Mhawech-Fauceglia, Paulette; Pejovic, Tanja; Zahn, Christopher M.; Wang, Guisong; Conrads, Thomas P.; Larry Maxwell, G.; Hamilton, Chad A.; Darcy, Kathleen M.; Syed, Viqar.

In: Gynecologic Oncology, Vol. 140, No. 3, 01.03.2016, p. 503-511.

Research output: Contribution to journalArticle

Hope, ER, Mhawech-Fauceglia, P, Pejovic, T, Zahn, CM, Wang, G, Conrads, TP, Larry Maxwell, G, Hamilton, CA, Darcy, KM & Syed, V 2016, 'Nestin: A biomarker of aggressive uterine cancers', Gynecologic Oncology, vol. 140, no. 3, pp. 503-511. https://doi.org/10.1016/j.ygyno.2015.12.015
Hope ER, Mhawech-Fauceglia P, Pejovic T, Zahn CM, Wang G, Conrads TP et al. Nestin: A biomarker of aggressive uterine cancers. Gynecologic Oncology. 2016 Mar 1;140(3):503-511. https://doi.org/10.1016/j.ygyno.2015.12.015
Hope, Erica R. ; Mhawech-Fauceglia, Paulette ; Pejovic, Tanja ; Zahn, Christopher M. ; Wang, Guisong ; Conrads, Thomas P. ; Larry Maxwell, G. ; Hamilton, Chad A. ; Darcy, Kathleen M. ; Syed, Viqar. / Nestin : A biomarker of aggressive uterine cancers. In: Gynecologic Oncology. 2016 ; Vol. 140, No. 3. pp. 503-511.
@article{2dee5f2d3e5e4ec590a4fde3a5a5db43,
title = "Nestin: A biomarker of aggressive uterine cancers",
abstract = "Objective Evidence of potential prognostic and predictive value for nestin was investigated in well-annotated uterine cancers (UCs). Methods Nestin expression and previously-published biomarkers were evaluated by immunohistochemistry (IHC) in UC tissue microarrays. Biomarkers were categorized as low vs. high, and nestin was cut at 10{\%} positive staining. Relationship between nestin and clinicopathologic factors, biomarkers and outcome were evaluated using exact/log-rank testing or logistic/Cox modeling. Results There were 323 eligible cases, 34{\%} had advanced stage disease, 37{\%} had type II disease, and 5{\%} were carcinosarcomas. High nestin, observed in 19{\%} of cases, was more common in advanced vs. early stage disease, type II cancers or uterine carcinosarcoma vs. type I cancers, grade 3 disease, positive lymphovascular space invasion (LVSI) and tumors > 6 cm (p <0.05). Nestin was inversely correlated with ER, PR and TFF3, and correlated with p53 and IMP3. Women with high vs. low nestin had worse progression-free survival (PFS) and cancer-specific survival overall, and worse PFS in the subset who received no adjuvant therapy or radiation, or had early stage, type I disease or tumors with both low and high ER, PR, TFF3, PTEN, p53 or IMP3. The relationship between nestin and PFS was independent of stage, LVSI and risk categorization but not type of UC. Conclusions High nestin was more common in UCs with aggressive features and poor outcome. Nestin may represent a predictive biomarker for treatment selection for patients previously considered to be lower risk and a candidate for no or radiation-based adjuvant therapy, and compliment ER/PR testing.",
keywords = "Biomarkers, Immunohistochemistry, Nestin, Predictive, Prognostic, TMA, Uterine cancer",
author = "Hope, {Erica R.} and Paulette Mhawech-Fauceglia and Tanja Pejovic and Zahn, {Christopher M.} and Guisong Wang and Conrads, {Thomas P.} and {Larry Maxwell}, G. and Hamilton, {Chad A.} and Darcy, {Kathleen M.} and Viqar Syed",
year = "2016",
month = "3",
day = "1",
doi = "10.1016/j.ygyno.2015.12.015",
language = "English (US)",
volume = "140",
pages = "503--511",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Nestin

T2 - A biomarker of aggressive uterine cancers

AU - Hope, Erica R.

AU - Mhawech-Fauceglia, Paulette

AU - Pejovic, Tanja

AU - Zahn, Christopher M.

AU - Wang, Guisong

AU - Conrads, Thomas P.

AU - Larry Maxwell, G.

AU - Hamilton, Chad A.

AU - Darcy, Kathleen M.

AU - Syed, Viqar

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Objective Evidence of potential prognostic and predictive value for nestin was investigated in well-annotated uterine cancers (UCs). Methods Nestin expression and previously-published biomarkers were evaluated by immunohistochemistry (IHC) in UC tissue microarrays. Biomarkers were categorized as low vs. high, and nestin was cut at 10% positive staining. Relationship between nestin and clinicopathologic factors, biomarkers and outcome were evaluated using exact/log-rank testing or logistic/Cox modeling. Results There were 323 eligible cases, 34% had advanced stage disease, 37% had type II disease, and 5% were carcinosarcomas. High nestin, observed in 19% of cases, was more common in advanced vs. early stage disease, type II cancers or uterine carcinosarcoma vs. type I cancers, grade 3 disease, positive lymphovascular space invasion (LVSI) and tumors > 6 cm (p <0.05). Nestin was inversely correlated with ER, PR and TFF3, and correlated with p53 and IMP3. Women with high vs. low nestin had worse progression-free survival (PFS) and cancer-specific survival overall, and worse PFS in the subset who received no adjuvant therapy or radiation, or had early stage, type I disease or tumors with both low and high ER, PR, TFF3, PTEN, p53 or IMP3. The relationship between nestin and PFS was independent of stage, LVSI and risk categorization but not type of UC. Conclusions High nestin was more common in UCs with aggressive features and poor outcome. Nestin may represent a predictive biomarker for treatment selection for patients previously considered to be lower risk and a candidate for no or radiation-based adjuvant therapy, and compliment ER/PR testing.

AB - Objective Evidence of potential prognostic and predictive value for nestin was investigated in well-annotated uterine cancers (UCs). Methods Nestin expression and previously-published biomarkers were evaluated by immunohistochemistry (IHC) in UC tissue microarrays. Biomarkers were categorized as low vs. high, and nestin was cut at 10% positive staining. Relationship between nestin and clinicopathologic factors, biomarkers and outcome were evaluated using exact/log-rank testing or logistic/Cox modeling. Results There were 323 eligible cases, 34% had advanced stage disease, 37% had type II disease, and 5% were carcinosarcomas. High nestin, observed in 19% of cases, was more common in advanced vs. early stage disease, type II cancers or uterine carcinosarcoma vs. type I cancers, grade 3 disease, positive lymphovascular space invasion (LVSI) and tumors > 6 cm (p <0.05). Nestin was inversely correlated with ER, PR and TFF3, and correlated with p53 and IMP3. Women with high vs. low nestin had worse progression-free survival (PFS) and cancer-specific survival overall, and worse PFS in the subset who received no adjuvant therapy or radiation, or had early stage, type I disease or tumors with both low and high ER, PR, TFF3, PTEN, p53 or IMP3. The relationship between nestin and PFS was independent of stage, LVSI and risk categorization but not type of UC. Conclusions High nestin was more common in UCs with aggressive features and poor outcome. Nestin may represent a predictive biomarker for treatment selection for patients previously considered to be lower risk and a candidate for no or radiation-based adjuvant therapy, and compliment ER/PR testing.

KW - Biomarkers

KW - Immunohistochemistry

KW - Nestin

KW - Predictive

KW - Prognostic

KW - TMA

KW - Uterine cancer

UR - http://www.scopus.com/inward/record.url?scp=84959573561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959573561&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2015.12.015

DO - 10.1016/j.ygyno.2015.12.015

M3 - Article

C2 - 26718725

AN - SCOPUS:84959573561

VL - 140

SP - 503

EP - 511

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -